Inhibikase Therapeutics Inc Stock Price, News & Analysis

Inhibikase Therapeutics (Nasdaq: IKT) reported Q2 2025 financial results and provided updates on its PAH drug development program. The company is preparing to launch IMPROVE-PAH, a Phase 2b clinical study for IKT-001, their re-engineered prodrug of imatinib mesylate, in the second half of 2025.

The study will involve 150 PAH participants randomized to receive either 300mg IKT-001, 500mg IKT-001, or placebo. Previous studies showed imatinib's efficacy in PAH, with patients on 400mg achieving a 45-meter improvement in 6-minute walk distance. The company ended Q2 2025 with $87.7 million in cash and reported a net loss of $9.9 million ($0.11 per share).

Inhibikase Therapeutics (NASDAQ: IKT) reported its Q1 2025 financial results and recent developments. The company reported a net loss of $13.7 million ($0.15 per share) compared to $4.6 million in Q1 2024. R&D expenses increased to $10.5 million, including a $7.4 million non-cash charge for the CorHepta acquisition. SG&A expenses rose to $5.2 million from $2.0 million year-over-year.

The company strengthened its leadership team with key appointments, including Mark Iwicki as CEO. IKT is advancing IKT-001 toward a Phase 2b clinical trial in Pulmonary Arterial Hypertension (PAH) expected to begin in H2 2025. The company maintains a strong cash position of $93.2 million as of March 31, 2025.

Inhibikase Therapeutics (Nasdaq: IKT) has appointed David McIntyre as Chief Financial Officer, effective April 14, 2025. McIntyre brings over two decades of executive experience in the life sciences sector, having served in C-suite positions at companies including Anthos Therapeutics, HeartWare International, AVITA Medical, Tessa Therapeutics, and Braeburn.

Prior to joining IKT, McIntyre was a Partner at Apple Tree Partners, a multi-billion-dollar life sciences venture capital fund. His background includes roles as a senior attorney at Baker McKenzie and KPMG, focusing on M&A, IPOs, and corporate law. He holds degrees from the University of Sydney, University of Technology Sydney, and an MBA from Duke University's Fuqua School of Business.

Inhibikase Therapeutics (IKT) reported its 2024 financial results and key developments, highlighting a strategic focus on advancing IkT-001 for Pulmonary Arterial Hypertension (PAH) treatment. The company secured $110 million through a private placement in October 2024, with potential additional proceeds of up to $275 million if warrants are exercised.

Key financial metrics for 2024 include:

• Net loss of $27.5 million ($1.16 per share) vs $19.1 million in 2023
• R&D expenses increased to $17.2 million from $13.6 million in 2023
• SG&A expenses rose to $11.4 million from $6.7 million in 2023
• Cash position of $97.5 million as of December 31, 2024

The company strengthened its leadership team with Mark Iwicki as CEO, Chris Cabell as President and Head of R&D, and John Adams as CSO. The FDA issued a Study May Proceed letter for IkT-001's Phase 2b trial in September 2024.

Inhibikase Therapeutics (Nasdaq: IKT) has announced significant leadership appointments, strengthening its executive team with expertise in pulmonary arterial hypertension (PAH). Chris Cabell, MD, former Chief Medical Officer of Arena Pharmaceuticals and CEO of CorHepta, joins as President and Head of Research & Development. John Adams, PhD, CorHepta co-founder and former Head of Research at Arena Pharmaceuticals, becomes Chief Scientific Officer.

The company also appointed Vince Aurentz to its Board of Directors, bringing extensive experience in corporate strategy and business development from his role as Executive VP and Chief Business Officer at Arena Pharmaceuticals, which was acquired by Pfizer for $6.7 billion in 2022.

These appointments aim to accelerate the preparation and execution of the IkT-001 Phase 2 clinical trial in PAH. Both Cabell and Adams have significant experience with PAH medicine development, notably with ralinepag, which was successfully licensed to United Therapeutics.

Inhibikase Therapeutics (Nasdaq: IKT) has announced significant leadership changes effective February 14, 2025. Mark Iwicki, with over 30 years of biopharmaceutical industry experience, has been appointed as CEO, replacing founder Dr. Milton H. Werner. Additionally, Amit Munshi has been named Chair of the Board, succeeding Roberto Bellini, who will continue as a director.

The company granted Iwicki substantial inducement awards, including options to purchase up to 15,061,377 shares total, with various vesting conditions. These awards were granted outside the company's 2020 Equity Incentive Plan as a material inducement to his employment.

The new leadership team will focus on advancing IkT-001Pro through clinical development, particularly for PAH (Pulmonary Arterial Hypertension) treatment, leveraging $110 million in proceeds from October financing.

Inhibikase Therapeutics (IKT) reported Q3 2024 financial results and secured transformative financing of up to $275 million from healthcare investors. The company received a Study May Proceed letter for IkT-001Pro in Pulmonary Arterial Hypertension (PAH) and added four new board members. Q3 net loss was $5.8 million ($0.65/share), with R&D expenses at $4.2 million and SG&A at $1.6 million. Cash position was $3.2 million as of September 30, excluding the recent $110 million private placement. The company expects topline data from the Phase 2 201 Trial of risvodetinib in Parkinson's disease in Q4 2024.

Inhibikase Therapeutics (Nasdaq: IKT) has closed a private placement of approximately $110 Million with potential aggregate financing of up to $275 Million. The funds will support the Phase 2b '702' trial of IkT-001Pro in Pulmonary Arterial Hypertension (PAH). IkT-001Pro, containing imatinib, is being developed as a New Molecular Entity and the first oral, potentially disease-modifying treatment for PAH, a rapidly fatal disease primarily affecting women aged 30-60.

The company has appointed four new Board members: Roberto Bellini (Independent Chairperson), Amit Munshi, Arvind Kush, and David Canner. This investment from top-tier healthcare funds recognizes IkT-001Pro's potential to improve PAH patients' lives by potentially addressing the safety and tolerability issues that prevented imatinib's approval over a decade ago.

Inhibikase Therapeutics (Nasdaq: IKT) has announced the pricing of a $110 million private placement to advance IkT-001Pro, an optimized prodrug of Imatinib, into a late-stage trial for Pulmonary Arterial Hypertension (PAH). The financing, led by Soleus Capital, involves selling 58,310,000 shares of common stock and pre-funded warrants for 21,985,000 shares, along with accompanying Series A-1 and B-1 warrants. The purchase price is $1.37 per share.

The company plans to use the proceeds to initiate a Phase 2b trial in PAH. The private placement is expected to close on October 21, 2024. Additionally, four new directors will join the company's board, including Roberto Bellini as Independent Chairperson.